Immediate and Long-Term Results of Drug-Eluting Stents in Mammary Artery Grafts

Lozano, Íñigo; Serrador, Ana; Palop, Ramón Lopéz; Lasa, Garikoitz; Moreu, José; Pinar, Eduardo; Prado, Armando Pérez de; Alfonso, Fernándo; Navarro, Manuel Jiménez; Quero, Mónica Fernández; Pineda, Javier; Moreiras, Javier Martín; Román, Koldobika García San; Mínguez, José Ramón López; Cuervo, A Suarez; Gutiérrez, Antonio; Hernández, Felipe; Baz, José Antonio; Benedicto, Amparo; Rumoroso, José Ramón; Gómez‐Hospital, Joan Antoni; Serra, Viçens; Torre, José María de la; Ruiz-Quevedo, Valeriano; Botas, Javier; Fernández, José Antonio; Sánchez‐Recalde, Ángel

doi:10.1016/j.amjcard.2015.08.040

Cited by 8 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 The classic mTOR inhibitors, rapalogs, are used in the coating of coronary stents, prevention of rejection after organ transplantation, treatment of tuberous sclerosis complex, and lymphangioleiomyomatosis. [31][32][33][34] Everolimus, a rapalog, has indications for the treatment of neuroendocrine tumors, advanced breast cancer in postmenopausal women who failed letrozole or anastrozole, and advanced renal cell carcinoma that failed sunitinib or sorafenib. [35][36][37] The main reason that rapalogs do not have wider indications in cancer is that their antitumor effect is modest whereas they have various adverse effects.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer

Kim

Lee

et al. 2019

Ther Adv Med Oncol

View full text Add to dashboard Cite

Objective: Leucyl-tRNA synthetase (LRS) is an aminoacyl-tRNA synthetase catalyzing ligation of leucine to its cognate tRNA and is involved in the activation of mTORC1 by sensing cytoplasmic leucine. In this study, the usefulness of LRS as a therapeutic target of non-small cell lung cancer (NSCLC) and the anticancer effect of the LRS inhibitor, BC-LI-0186, was evaluated. Methods: LRS expression and the antitumor effect of BC-LI-0186 were evaluated by immunohistochemical staining, immunoblotting, and live cell imaging. The in vivo antitumor effect of BC-LI-0186 was evaluated using Lox-Stop-Lox (LSL) K-ras G12D mice. Results: LRS was frequently overexpressed in NSCLC tissues, and its expression was positively correlated with mTORC1 activity. The guanosine-5’-triphosphate (GTP) binding status of RagB was related to the expression of LRS and the S6K phosphorylation. si RNA against LRS inhibited leucine-mediated mTORC1 activation and cell growth. BC-LI-0186 selectively inhibited phosphorylation of S6K without affecting phosphorylation of AKT and leucine-mediated co-localization of Raptor and LAMP2 in the lysosome. BC-LI-0186 induced cleaved poly (ADP-ribose) polymerase (PARP) and caspase-3 and increase of p62 expression, showing that it has the autophagy-inducing property. BC-LI-0186 has the cytotoxic effect at nanomolar concentration and its GI 50 value was negatively correlated with the degree of LRS expression. BC-LI-0186 showed the antitumor effect, which was comparable with that of cisplatin, and mTORC1 inhibitory effect in a lung cancer model. Conclusions: BC-LI-0186 inhibits the noncanonical mTORC1-activating function of LRS. These results provide a new therapeutic strategy for NSCLC and warrant future clinical development by targeting LRS.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer

Kim

Lee

et al. 2019

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…Gruberg et al reported a higher use of simple PCI for distal lesions (anastomotic), while ostial lesions were managed more frequently with stents), with good clinical results up to 12 months 22 . Overall, this retrospective study reported higher target lesion revascularization rate for stenting (15.4%) compared with simple PCI (5.4%), at one year 21 …”

Section: Discussionmentioning

confidence: 58%

“…Currently, DES has been deemed to be the first choice because its lower rates of in stent restenosis, compared with BMS 19, 20. Recently, a 27-center registry by Lozano et al on the use of DES in 268 patients with a failed mammary graft, reported good long-term results 21 …”

Section: Discussionmentioning

confidence: 99%

Internal mammary artery graft failure: Clinical features, management, and long-term outcomes

Núñez‐Gil

Alfonso

Salinas

et al. 2018

Indian Heart Journal

View full text Add to dashboard Cite

ObjectiveData on long-term outcomes after internal mammary artery (IMA) coronary graft failure are scarce. Our objective was to describe the clinical characteristics, management, and prognosis after angiographically confirmed IMA graft failure following coronary revascularization.MethodsA three-hospital retrospective registry, observational and descriptive, with prospective follow-up of all consecutive cases of IMA graft failure between 2004 and 2014 was conducted. After treatment, clinical and procedural features were compared between those with and without cardiovascular events.ResultsFifty-seven patients were included (89% male, mean age: 62 years, at surgery) in the registry. Most patients underwent an IMA angioplasty (percutaneous coronary intervention [PCI], 74%). In nine cases, the PCI failed at the graft level, and seven underwent a native vessel revascularization. Native vessel treatment was performed in 20% of the study subjects, all with stents. Finally, medical management was decided in three cases. Events after treatment for IMA graft failure were frequent (50.8%), during a median follow-up of 7.5 years. Acute presentation (hazard ratioMACE = 1.35; 95% confidence interval (CI): 1.12–3.00, p < 0.01), age of the patient (hazard ratioMACE = 1.85, 95% CI: 1.17–2.11, p < 0.01), presence of diabetes mellitus (hazard ratioMACE = 2.75, 95% CI: 1.13–6.69, p = 0.02), and the management modality used (IMA-simple angioplasty VS IMA-stenting: hazard ratioMACE = 5.5, 95% CI: 1.40–21.15, p = 0.01) displayed prognostic relevance on multivariate analysis. All-cause mortality occurred in 21.1% and presentation as infarction (hazard ratioDEATH = 1.05, 95% CI: 1.01–2.17, p = 0.01), age (hazard ratioDEATH = 9.08, 95% CI: 2.52–32.69, p < 0.01), and left ventricular ejection fraction (hazard ratioDEATH = 3.68, 95% CI: 1.65–8.18, p < 0.01) were independent predictors of the same.ConclusionsIn this long-term registry, most patients presented with an acute condition (myocardial infarction, progressive angina) within 12 months after surgery. Acute presentation, age, diabetes mellitus, reduced left ventricular ejection fraction, IMA graft failure segment affected, and the management strategy were related with long-term prognosis.

show abstract

Secondary Percutaneous Revascularization After Coronary Artery Bypass Graft Surgery

Vílchez-Tschischke

Mejía‐Rentería

Gonzalo

et al. 2018

The Interventional Cardiology Training Manual

View full text Add to dashboard Cite

Immediate and Long-Term Results of Drug-Eluting Stents in Mammary Artery Grafts

Cited by 8 publications

References 18 publications

Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer

Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer

Internal mammary artery graft failure: Clinical features, management, and long-term outcomes

Secondary Percutaneous Revascularization After Coronary Artery Bypass Graft Surgery

Contact Info

Product

Resources

About